News

Asuragen to Collaborate with Illumina on Companion Diagnostics Development

Austin, Texas – Date: September 9, 2015Asuragen, Inc., a global molecular diagnostics company, announced today that it had entered into a collaboration agreement with Illumina, Inc. (NASDAQ:ILMN) that establishes a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies.

Asuragen will leverage its QuantideX® NGS product platform for development of customized companion diagnostics for its biotech and pharma partners on the Illumina MiSeqDx™ instrument. Asuragen’s recently launched QuantideX® Pan Cancer Kit* demonstrates its optimized NGS system that unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification, using reagents provided in a single kit. In addition, it integrates Asuragen’s analytics and reporting suite, the QuantideX® Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels.

“We are uniquely positioned to be a nimble and high quality companion diagnostic partner to biotech and pharma”, said Matt McManus, President and CEO of Asuragen. “Sequencing-based companion diagnostic projects benefit from our established QuantideX® NGS product platform, which allows for rapid and efficient development of a unique DNA and/or RNA panel of interest. The Quantidex™ NGS system is built under design control and manufactured in our cGMP facility, providing a high quality basis for regulated diagnostic product development.”

* For Research Purposes Only. Not for use in diagnostic procedures.

About Asuragen
Asuragen is a molecular diagnostics company driving better patient management in oncology and genetic disorders through best-in-class clinical testing solutions. The company uses a breadth of technologies and scientific talent to discover, develop and commercialize diagnostic products for clinical laboratories and for our Bio/Pharma partners. Asuragen’s development of innovative diagnostic products will help transform medicine by improving clinical outcomes and health economics. For more information, visit www.asuragen.com.

Contact:
Lynne Hohlfeld
SVP, Corporate Development and Chief Financial Officer
Asuragen, Inc.
512.681.5200
lhohlfeld@asuragen.com
www.asuragen.com

###

Back To
Top